Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Ludovica Morera, Michael Lübbert, Manfred Jung
Read Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy by Ludovica Morera, Michael Lübbert, Manfred Jung in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4877953.txt.
Description
Ludovica Morera, Michael Lübbert, and Manfred Jung reviewed drugs in early trials that target histone methylation enzymes for cancer care. Epigenetic marks steer gene use without changing DNA letters, and their faults help cancers start and grow. Unlike mutations, marks can be reversed, which makes their writer and eraser enzymes inviting drug targets.
The review covers lysine methyl writers and erasers whose blockers reached first-stage clinical trials. Early results, dosing snags, and patient selection all get weighed. Some enzymes matter only in certain tumor types, so matching drug to tumor is key. The field is young, but marks once seen as fixed scenery now look like handles for treatment.
Catalog record
| CREATOR | Ludovica Morera, Michael Lübbert, Manfred Jung |
|---|---|
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |